Q-omics provides the consensus-scored TP53I3 profile across patient tissues and cancer cell-line models. TP53I3 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, TP53I3 is differentially expressed in 12, with the highest sampling consensus in COAD. Additionally, TP53I3 protein abundance shows 19,899 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight ACC, COAD, and PDAC as cancer lineages where TP53I3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TP53I3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TP53I3 survival associations across molecular data types. TP53I3 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (1) and mass-spec protein abundance (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TP53I3 RNA expression–survival associations across cancer types. High TP53I3 expression shows unfavorable associations in ACC, SKCM, LUAD, LGG, CESC and LIHC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for TP53I3 RNA expression.
This table summarizes TP53I3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 12. The strongest signals are observed in COAD for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for TP53I3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TP53I3 shows lower tumor expression in COAD, KICH and READ and higher tumor expression in LIHC, UCEC and CHOL. The COAD box plot shows higher TP53I3 RNA expression in normal versus tumor tissue (log2 FC = −0.878, t-test p < 0.001).
This table shows molecular features associated with TP53I3 in patient tissues and cancer cell lines. In patient samples, TP53I3 shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, TP53I3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in BONE and OESOPHAGUS.
